Predictive Value of Maternal Blood Protein Signatures in Preterm Birth
NCT ID: NCT06664554
Last Updated: 2024-12-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
18000 participants
OBSERVATIONAL
2021-01-01
2024-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study aims to evaluate the prediction performance of new maternal blood biomarkers (proteomic markers) on the occurrence of preterm birth.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Emphasizing its significant public health ramifications, PTB is recognized as a primary contributor to mortality among children under five, particularly with 40% of deaths occurring within the first month of life in this demographic. Following PTB, infants face an increased vulnerability to severe complications like respiratory distress syndrome, intraventricular hemorrhage, and necrotizing enterocolitis, accentuating the acute threats to infant well-being and longevity. Addressing these early-life hurdles requires the formulation of robust strategies for prediction and prevention to alleviate the immediate hazards linked with premature birth.
Preventing PTB crucially depends on accurately identifying women at high risk. Interventions like vaginal progesterone and cervical cerclage are recommended for those with a short cervical length. However, the effectiveness of these strategies is frequently compromised by limitations in current screening methods, which struggle to accurately predict PTB. This underscores a significant gap in effectively identifying all at-risk women, underscoring the necessity for enhanced screening techniques to more precisely pinpoint women who would benefit from preventive interventions.
Current screening methods, primarily based on measuring cervical length and assessing historical risk factors, are inadequate in capturing the multifaceted nature of PTB risk, leading to missed opportunities for intervention and prevention. This inadequacy underscores the importance of developing methods that can more accurately identify women at high risk. Research efforts aimed at addressing these challenges suggest the potential of integrating new biomarkers and maternal characteristics into screening protocols to improve the predictive accuracy of PTB screenings.
Building upon the premise that the placenta plays a pivotal role in fetal health regulation, and that insights into the pathologic mechanisms leading to spontaneous preterm birth can be gleaned from the placental transcriptome, the investigators utilized existing transcriptomic data from the public domain, employing bioinformatics methodologies. This data was further complemented by quantitative proteomics analysis techniques using mass spectrometry. Through this integrated approach, the investigators have developed a novel PTB screening panel comprising three protein biomarkers. The efficacy and prediction performance of this three-protein predictor will be evaluated in this study with independent cohorts.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Preterm birth
Pregnancy with delivery before 37 weeks of gestational age
No interventions assigned to this group
Term birth control
Pregnancy with delivery at 37 weeks or later of gestational age
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Single pregnancy
* Consent to participate in the study
Exclusion Criteria
* Uterine malformation
* Fetal malformation
* Pregestational Diabetes
* Systemic diseases (chronic kidney disease, autoimmune disease, etc.)
* Serious medical illness (renal insufficiency, congestive heart disease, chronic respiratory insufficiency, etc.).
* Suffering from other disease unfavorable to the trial such as metal illness
* Any maternal or fetal condition that requires termination of pregnancy.
* Active vaginal bleeding.
* Multifetal pregnancy with greater than or equal to 2 fetuses.
* Lack of clinical outcome or incomplete basic information
* Iatrogenic premature delivery or induced labor
* Lack of consent.
18 Years
45 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shenzhen Maternity & Child Healthcare Hospital
OTHER
HBI Solutions Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Qiong Luo
M.D., Ph.D.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Qiong Luo, M.D. Ph.D.
Role: PRINCIPAL_INVESTIGATOR
Department of Obstetrics, Women's Hospital of Zhejiang University, School of Medicine, Hangzhou, 310006, China
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Obstetrics and Gynecology, the Eighth Affiliated Hospital, Sun Yat-sen University;
Shenzhen, Guangdong, China
Department of Obstetrics, Shenzhen Maternity and Child Healthcare Hospital
Shenzhen, Guangdong, China
Department of Obstetrics and Gynecology, The Third Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Hunan Provincial Maternal and Child Health Care Hospital
Changsha, Hunan, China
Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University,
Jinan, Shandong, China
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Romero R, Dey SK, Fisher SJ. Preterm labor: one syndrome, many causes. Science. 2014 Aug 15;345(6198):760-5. doi: 10.1126/science.1251816. Epub 2014 Aug 14.
Boyle AK, Rinaldi SF, Norman JE, Stock SJ. Preterm birth: Inflammation, fetal injury and treatment strategies. J Reprod Immunol. 2017 Feb;119:62-66. doi: 10.1016/j.jri.2016.11.008. Epub 2016 Dec 2.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PTB_01
Identifier Type: -
Identifier Source: org_study_id